(Q38014716)

27 August 2017

title

Should mycophenolate mofetil replace cyclophosphamide as first-line therapy for severe lupus nephritis? (English)

1 reference

27 August 2017

Jonathan Hogan

1

1 reference

27 August 2017

Michael H Schwenk

series ordinal

2

1 reference

27 August 2017

Jai Radhakrishnan

series ordinal

3

1 reference

27 August 2017

language of work or name

English

0 references

publication date

30 May 2012

1 reference

27 August 2017

1 reference

27 August 2017

volume

82

1 reference

27 August 2017

issue

12

1 reference

27 August 2017

page(s)

1256-1260

1 reference

The very long-term prognosis and complications of lupus nephritis and its treatment

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.203

7 January 2021

Three decades of progress in treating childhood-onset lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.203

7 January 2021

Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.203

7 January 2021

Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.203

7 January 2021

Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.203

7 January 2021

The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.203

7 January 2021

Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.203

7 January 2021

Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.203

7 January 2021

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.203

7 January 2021

Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.203

7 January 2021

Mycophenolate therapy of SLE membranous nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.203

7 January 2021

Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.203

7 January 2021

Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.203

7 January 2021

Effects of mycophenolate mofetil for patients with crescentic lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.203

7 January 2021

Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: mycophenolate mofetil or intravenous cyclophosphamide

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.203

7 January 2021

Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.203

7 January 2021

Quality of life comparison between corticosteroid- and-mycofenolate mofetil and corticosteroid- and-oral cyclophosphamide in the treatment of severe lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.203

7 January 2021

Sequential therapies for proliferative lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.203

7 January 2021

Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.203

7 January 2021

Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.203

7 January 2021

Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ethnicity

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.203

7 January 2021

Severe lupus nephritis: racial differences in presentation and outcome

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.203

7 January 2021

Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.203

7 January 2021

Geographical variation in the response of lupus nephritis to mycophenolate mofetil induction therapy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.203

7 January 2021

Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.203

7 January 2021

Efficacy and adverse events of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.203

7 January 2021

Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and metaanalysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.203

7 January 2021

Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.203

7 January 2021

Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.203

7 January 2021

Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.203

7 January 2021

Cyclophosphamide: new approaches for systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.203

7 January 2021

Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.203

7 January 2021

Oral cyclophosphamide for lupus glomerulonephritis: an underused therapeutic option

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.203

7 January 2021

The cost-effectiveness of mycophenolate mofetil as firstline therapy in active lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.203

7 January 2021

Cost comparison between mycophenolate mofetil and cyclophosphamide-azathioprine in the treatment of lupus nephritis.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.203

7 January 2021

The effects of cyclophosphamide and mycophenolate on end-stage renal disease and death of lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.203

7 January 2021

Identifiers

DOI

10.1038/KI.2012.203

1 reference

Dimensions Publication ID

27 August 2017

1050550013

0 references

1 reference